Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Sell
27
INM Quote, Financials, Valuation and Earnings
Last price:
$1.22
Seasonality move
:
14.22%
Day range:
$1.12 - $1.24
52-week range:
$1.12 - $8.27
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.48x
P/B ratio:
0.29x
Volume:
313.3K
Avg. volume:
648.9K
1-year change:
-74.89%
Market cap:
$3.3M
Revenue:
$4.9M
EPS (TTM):
-$6.91
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, InMed Pharmaceuticals, Inc. has 34305.05% upside to fair value with a price target of -- per share.
INM vs. S&P 500
-
Over the past 5 trading days, InMed Pharmaceuticals, Inc. has overperformed the S&P 500 by 0.38% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
InMed Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
InMed Pharmaceuticals, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter InMed Pharmaceuticals, Inc. reported revenues of $1.1M.
Earnings Growth
-
InMed Pharmaceuticals, Inc. has grown year-over-year earnings for 5 quarters straight. In the most recent quarter InMed Pharmaceuticals, Inc. reported earnings per share of -$0.44.
Enterprise value:
-5.4M
EV / Invested capital:
-0.44x
Price / LTM sales:
0.48x
EV / EBIT:
--
EV / Revenue:
-1.12x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
0.71x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$1.1M
Return On Assets:
-71.79%
Net Income Margin (TTM):
-171.13%
Return On Equity:
-88.06%
Return On Invested Capital:
-80.72%
Operating Margin:
-157.46%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $4.7M | $5M | $4.8M | $1.3M | $1.1M | |
| Gross Profit | $1.2M | $884.6K | $1.1M | $348.4K | $246.5K | |
| Operating Income | -$7.5M | -$7.5M | -$7.9M | -$1.8M | -$1.8M | |
| EBITDA | -$6.9M | -$6.9M | -$7.4M | -$1.6M | -$1.6M | |
| Diluted EPS | -$47.55 | -$14.34 | -$6.91 | -$2.71 | -$0.44 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $16M | $11.5M | $8.3M | $7.3M | $10.8M | |
| Total Assets | $17.3M | $14.6M | $10.9M | $10.5M | $13.4M | |
| Current Liabilities | $1.9M | $3.3M | $1.3M | $1.4M | $1.6M | |
| Total Liabilities | $2.1M | $3.6M | $1.3M | $2.1M | $1.8M | |
| Total Equity | $15.2M | $11M | $9.6M | $8.4M | $11.6M | |
| Total Debt | $178.6K | $294.3K | -- | $633.8K | $215.5K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$7.2M | -$6.6M | -$7.6M | -$1.8M | -$1.6M | |
| Cash From Investing | -$660.1K | -$9.2K | -- | -- | -- | |
| Cash From Financing | $5.2M | $5.4M | $11.4M | $838.2K | -$137.2K | |
| Free Cash Flow | -$7.3M | -$6.6M | -$7.6M | -$1.8M | -$1.6M | |
INM
Sector
Market Cap
$3.3M
$27.9M
Price % of 52-Week High
14.39%
50.56%
Dividend Yield
0%
0%
Shareholder Yield
-198.64%
-1.55%
1-Year Price Total Return
-74.9%
-17.49%
Beta (5-Year)
0.313
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.24
200-day SMA
Sell
Level
$2.32
Bollinger Bands (100)
Sell
Level
1.49 - 2.31
Chaikin Money Flow
Sell
Level
-185.5M
20-day SMA
Sell
Level
$1.29
Relative Strength Index (RSI14)
Sell
Level
40.25
ADX Line
Sell
Level
19.18
Williams %R
Buy
Level
-80.6227
50-day SMA
Sell
Level
$1.56
MACD (12, 26)
Sell
Level
-0.09
25-day Aroon Oscillator
Sell
Level
-60
On Balance Volume
Neutral
Level
237.3M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-9.2256)
Sell
CA Score
(Annual)
Level (-1.4314)
Buy
Beneish M-Score
(Annual)
Level (-2.6473)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (7.0513)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
InMed Pharmaceuticals, Inc. engages in developing small molecule drug candidates targeting the CB1/CB2 receptors. It operates through the InMed Pharma and BayMedica Commercial segments. The InMed Pharma segment focuses on research and development. The BayMedica Commercial segment refers to manufacturing technologies to produce and commercialize bulk cannabinoids for sale as ingredients in the health and wellness industry. The company was founded by Christopher Bogart, Sazzad Hossain, Hyder A. Khoja, and Craig D. Schneider on May 19, 1981 and is headquartered in Vancouver, Canada.
Stock Forecast FAQ
In the current month, INM has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The INM average analyst price target in the past 3 months is --.
-
Where Will InMed Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that InMed Pharmaceuticals, Inc. share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About InMed Pharmaceuticals, Inc.?
Analysts are divided on their view about InMed Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that InMed Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to --.
-
What Is InMed Pharmaceuticals, Inc.'s Price Target?
The price target for InMed Pharmaceuticals, Inc. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is INM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for InMed Pharmaceuticals, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of INM?
You can purchase shares of InMed Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase InMed Pharmaceuticals, Inc. shares.
-
What Is The InMed Pharmaceuticals, Inc. Share Price Today?
InMed Pharmaceuticals, Inc. was last trading at $1.22 per share. This represents the most recent stock quote for InMed Pharmaceuticals, Inc.. Yesterday, InMed Pharmaceuticals, Inc. closed at $1.19 per share.
-
How To Buy InMed Pharmaceuticals, Inc. Stock Online?
In order to purchase InMed Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get INM Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
INM
Sector
P/E ratio
--
23.75x
PEG ratio
0.00x
-0.01x
P/B ratio
0.29x
1.81x
Price / LTM sales
0.48x
1.59x
Growth Metrics
INM
Sector
Revenue growth
-11.43%
4.6%
Earnings growth
83.86%
10.88%
Revenue (5-year growth)
--
6.45%
Earnings forecast
--
-$0.21
Profitability
INM
Sector
Profitability FY 2025
$1.2M
$3.6M
Return on invested capital
-80.72%
-31.84%
Return on assets
-71.79%
-27.96%
Return on equity
-88.06%
-37.63%
Earnings Date
Last Earnings Date
Dec
30
Next Earnings Date
Dec
30
Estimated Next Earnings Date
Mar
31
Balance Sheet
INM
Sector
Total cash
$9.4M
$26.3M
Short term investments
--
$25.7M
Total assets
$15.6M
$76.9M
Long term debt
$215.5K
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
14
SMX alert for Dec 30
SMX (Security Matters) Plc [SMX] is down 36.69% over the past day.
Buy
71
ZCSH alert for Dec 30
Grayscale Zcash Trust (ZEC) [ZCSH] is down 1.56% over the past day.
Buy
69
GDXU alert for Dec 30
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is up 4.26% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
